Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.43 |
| ▸ | CDK9 | P50750 | 7/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.42 |
| ▸ | TNKS | O95271 | 3/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648202 | 0.83 | KDM4E (0.41) | CDK9CCNT1TNKSMAPTTHRB | |
| SCHEMBL3442265 | 0.83 | TNKS (0.46) | CDK9CCNT1TNKSTNKS2MAPT | |
| SCHEMBL6649390 | 0.82 | TNKS (0.45) | CDK9CCNT1TNKSTNKS2 | |
| Hydrochloric Acid SCHEMBL3442524 | 0.82 | HTR2C (0.47) | CDK9CCNT1TNKSTNKS2MAPT | |
| SCHEMBL6645471 | 0.80 | TNKS (0.52) | CDK9CCNT1TNKSTNKS2HTR2C | |
| Hydrochloric Acid SCHEMBL3442229 | 0.77 | KDM4E (0.46) | MAPTTHRBPLGHTR2C | |
| Bromide SCHEMBL6643622 | 0.77 | KDM4E (0.46) | MAPTTHRBPLG | |
| SCHEMBL3443155 | 0.75 | PARP14 (0.44) | TNKSHTR2C | |
| Hydrochloric Acid SCHEMBL3443035 | 0.74 | PARP14 (0.43) | TNKSHTR2C | |
| SCHEMBL2212767 | 0.73 | DAO (0.52) | HTR1ASLC6A2SLC6A4SLC6A3TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | claimed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | claimed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | HTR1A 2632/4885SLC6A2 2718/4885SLC6A4 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.